siRNA Therapy: Mechanism, Applications, and Clinical Potential

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to siRNA Therapy

What is siRNA?

Small interfering RNA (siRNA) is a class of double-stranded RNA molecules, typically 20–24 nucleotides in length, that mediate sequence-specific gene silencing through the RNA interference (RNAi) pathway. Each siRNA duplex consists of a guide (antisense) strand and a passenger (sense) strand, with characteristic two-nucleotide 3′ overhangs on both ends. The guide strand is complementary to a target messenger RNA (mRNA) sequence, and its incorporation into the RNA-induced silencing complex (RISC) directs the cleavage and degradation of that specific mRNA, thereby preventing translation of the corresponding protein.

RNA interference is an evolutionarily conserved mechanism present in eukaryotes ranging from fungi to plants to mammals. It is believed to have originated as a defense against viral infection and transposable element mobilization, but it has since been co-opted as a powerful experimental and therapeutic tool. The discovery of RNAi, first characterized in Caenorhabditis elegans by Fire and Mello in 1998, earned the Nobel Prize in Physiology or Medicine in 2006 and laid the foundation for the development of siRNA-based therapeutics.

Therapeutic Relevance

The therapeutic rationale for siRNA therapy is straightforward: if a disease is caused by the overexpression of a particular gene or by the production of a mutant protein, then silencing that gene at the mRNA level should ameliorate the disease phenotype. Unlike traditional small-molecule drugs that inhibit protein function, siRNA acts upstream at the mRNA level, which offers several advantages. First, siRNA can theoretically target any gene whose sequence is known, including those encoding proteins that are considered "undruggable" by conventional small molecules—such as transcription factors, scaffolding proteins, and long non-coding RNAs. Second, because siRNA exploits the endogenous RNAi machinery, it achieves catalytic gene silencing: a single siRNA-loaded RISC can cleave multiple mRNA transcripts, providing potent and sustained knockdown.

The first siRNA therapeutic, patisiran, was approved by the U.S. Food and Drug Administration (FDA) in 2018 for the treatment of hereditary transthyretin-mediated amyloidosis. Since then, several additional siRNA drugs have received regulatory approval, and many more are in clinical development. The field has matured from a laboratory curiosity to a clinically validated therapeutic modality, with ongoing efforts focused on expanding delivery capabilities, improving specificity, and addressing a broader range of diseases.

Mechanism of siRNA Therapy

RNAi Pathway

The RNAi pathway can be divided into two phases: initiation and effector. In the initiation phase, long double-stranded RNA (dsRNA) is processed by the RNase III enzyme Dicer into mature siRNA duplexes. Dicer recognizes dsRNA substrates and cleaves them at a defined distance from the ends, generating fragments of 21–23 nucleotides with 2-nucleotide 3′ overhangs and 5′ phosphate groups. In the context of exogenous siRNA therapy, synthetic siRNA duplexes are designed to mimic the products of Dicer cleavage, thereby bypassing the need for Dicer processing and entering the pathway directly at the effector phase.

The effector phase begins with the loading of the siRNA duplex into the RNA-induced silencing complex. The core component of RISC is an Argonaute (Ago) protein, specifically Ago2 in mammals, which possesses endonucleolytic (slicer) activity. Ago2 binds the siRNA duplex and subsequently unwinds it, retaining the guide strand while the passenger strand is discarded and degraded. Strand selection is governed by the relative thermodynamic stability of the two ends of the duplex: the strand whose 5′ end is less stably base-paired is preferentially loaded as the guide strand. This asymmetry is critical for ensuring that the correct strand enters RISC and that off-target silencing is minimized.

RISC Assembly and Target Recognition

The mature RISC, containing the guide strand bound to Ago2, scans cytoplasmic mRNAs for complementary sequences. Target recognition is governed by the seed region of the guide strand—nucleotides 2–8 from the 5′ end—which must base-pair with perfect complementarity to the target mRNA for efficient silencing. Full complementarity across the entire guide strand is required for Ago2-mediated cleavage; however, partial complementarity, particularly in the seed region, can also lead to translational repression and mRNA destabilization through mechanisms similar to those used by microRNAs (miRNAs). This distinction is important because it underlies both the potency and the potential for off-target effects of siRNA therapeutics.

The loading of the guide strand into Ago2 is an ATP-dependent process facilitated by the chaperone proteins Hsp70 and Hsp90, which maintain Ago2 in an open conformation capable of accepting the duplex. Once the guide strand is loaded, the passenger strand is removed, and the activated RISC is released to find its target. The entire process from siRNA delivery to functional RISC formation typically occurs within hours, with maximal gene silencing observed 24–72 hours after transfection in cultured cells.

mRNA Degradation

When the guide strand of RISC finds a fully complementary mRNA, Ago2 cleaves the phosphodiester backbone of the target mRNA between nucleotides 10 and 11 relative to the 5′ end of the guide strand. This cleavage generates mRNA fragments with a 5′ phosphate and a 3′ hydroxyl group, which are subsequently degraded by cellular exonucleases. The cleaved mRNA is rapidly eliminated, and the RISC is recycled to cleave additional mRNA molecules. This catalytic mechanism means that a single RISC can silence hundreds to thousands of mRNA transcripts, providing sustained knockdown that can persist for weeks in non-dividing cells.

In addition to Ago2-mediated cleavage, siRNA can also induce gene silencing through transcriptional repression. In the nucleus, siRNA-loaded RISC can recruit histone methyltransferases and DNA methyltransferases to complementary genomic loci, leading to heterochromatin formation and transcriptional gene silencing. While this mechanism is well-characterized in plants and fission yeast, its relevance in mammalian cells is less clear and remains an area of active investigation.

Design and Delivery of siRNA Therapeutics

siRNA Design Principles

The design of an effective siRNA requires careful consideration of several parameters to maximize potency and minimize off-target effects. The guide strand should be 19–21 nucleotides in length with a 2-nucleotide 3′ overhang on the passenger strand. The 5′ end of the guide strand should be phosphorylated to facilitate Ago2 loading. Sequence composition influences strand selection: the guide strand should have a lower thermodynamic stability at its 5′ end compared to the passenger strand, typically achieved by incorporating A/U base pairs at the 5′ end of the guide strand and G/C base pairs at the 5′ end of the passenger strand.

Target site selection within the mRNA is also critical. The target region should be accessible—that is, not buried within highly structured RNA or bound by RNA-binding proteins. Computational algorithms, such as those available through the Design siRNA resource, predict target accessibility and rank candidate siRNAs based on thermodynamic properties, seed region composition, and off-target potential. Typically, multiple siRNAs targeting different regions of the same mRNA are designed and screened empirically to identify the most potent and specific candidate.

Chemical modifications are almost always incorporated into therapeutic siRNAs to improve their drug-like properties. The most common modifications include 2′-O-methyl (2′-OMe), 2′-fluoro (2′-F), and 2′-O-methoxyethyl (2′-MOE) substitutions on the ribose sugar, as well as phosphorothioate (PS) backbone linkages. These modifications confer resistance to nucleases, reduce immune stimulation, and enhance binding affinity to the target mRNA. The 2′-OMe modification at specific positions, particularly in the seed region, can also reduce off-target effects by destabilizing binding to partially complementary mRNAs. The pattern of modifications must be carefully optimized, as excessive modification can impair RISC loading and silencing activity.

Delivery Challenges

The delivery of siRNA to target cells in vivo remains the single greatest challenge in siRNA therapy. Naked siRNA is rapidly degraded by serum nucleases, has a short half-life in circulation (typically minutes), and is poorly taken up by cells due to its large molecular weight (~13 kDa) and high negative charge. Furthermore, siRNA is filtered by the kidneys and cleared rapidly from the bloodstream. To overcome these barriers, siRNA must be formulated in delivery vehicles or chemically conjugated to targeting moieties.

The ideal delivery vehicle should protect the siRNA from degradation, facilitate cellular uptake, promote endosomal escape, and release the siRNA into the cytoplasm where RISC is located. Endosomal escape is particularly challenging: after cellular uptake via endocytosis, siRNA-containing particles are trafficked through the endolysosomal pathway, and if they fail to escape the endosome, they are degraded in lysosomes. The efficiency of endosomal escape for most delivery systems is estimated to be only 1–5%, meaning that the vast majority of internalized siRNA is non-functional.

Lipid Nanoparticles and Conjugates

Lipid nanoparticles (LNPs) are the most clinically advanced delivery system for siRNA. LNPs are typically composed of an ionizable cationic lipid, a phospholipid, cholesterol, and a polyethylene glycol (PEG)-lipid conjugate. The ionizable lipid is positively charged at acidic pH, which facilitates encapsulation of the negatively charged siRNA during formulation and promotes endosomal escape through the proton sponge effect. At physiological pH, the LNP surface is nearly neutral, reducing non-specific interactions with serum proteins and cells. The PEG-lipid provides a steric barrier that prevents aggregation and extends circulation time.

Patisiran, the first approved siRNA drug, uses an LNP formulation for delivery to hepatocytes. The LNPs are taken up by the liver via apolipoprotein E-mediated endocytosis, and the siRNA is released into the cytoplasm where it silences the transthyretin (TTR) gene. The success of patisiran validated the LNP platform and paved the way for subsequent LNP-based siRNA therapeutics.

An alternative approach is the use of N-acetylgalactosamine (GalNAc) conjugates. GalNAc is a sugar that binds with high affinity to the asialoglycoprotein receptor (ASGPR), which is expressed almost exclusively on hepatocytes. Covalent conjugation of siRNA to GalNAc enables targeted delivery to the liver after subcutaneous injection. GalNAc-siRNA conjugates are taken up by ASGPR-mediated endocytosis, and the siRNA is released into the cytoplasm. Inclisiran, an siRNA targeting PCSK9 for the treatment of hypercholesterolemia, uses this approach and has demonstrated durable gene silencing with twice-yearly dosing. The GalNAc platform has largely supplanted LNPs for liver-targeted siRNA therapies due to its improved tolerability, simpler manufacturing, and more convenient subcutaneous administration.

Examples of siRNA Therapies

Approved siRNA Drugs

Several siRNA therapeutics have received regulatory approval, and their success has validated the RNAi platform for clinical use.

Patisiran was the first siRNA drug approved by the FDA. It targets the TTR gene, which encodes transthyretin, a protein that transports thyroxine and retinol-binding protein. Mutations in TTR cause the protein to misfold and aggregate as amyloid fibrils, leading to progressive peripheral neuropathy and cardiomyopathy. Patisiran silences both wild-type and mutant TTR mRNA, reducing the production of the amyloidogenic protein. In clinical trials, patisiran improved polyneuropathy scores and quality of life measures in patients with hereditary transthyretin amyloidosis.

Givosiran targets ALAS1, the gene encoding aminolevulinate synthase 1, the rate-limiting enzyme in heme biosynthesis. In acute hepatic porphyria, partial deficiency of enzymes downstream of ALAS1 leads to accumulation of neurotoxic heme precursors. Givosiran reduces ALAS1 mRNA, thereby decreasing the production of these precursors and preventing acute attacks.

Inclisiran targets PCSK9, a protein that promotes the degradation of the low-density lipoprotein (LDL) receptor. By silencing PCSK9, inclisiran increases LDL receptor expression on hepatocytes, leading to enhanced clearance of LDL cholesterol from the blood. Inclisiran is administered subcutaneously twice a year and produces sustained LDL cholesterol reduction of approximately 50%, comparable to that achieved with monoclonal antibody inhibitors of PCSK9.

siRNA in Clinical Trials

Beyond the approved drugs, numerous siRNA therapeutics are in clinical development for a wide range of diseases. Fitusiran, targeting antithrombin (SERPINC1), is in Phase 3 trials for hemophilia A and B. By reducing antithrombin levels, fitusiran enhances thrombin generation and improves hemostasis in patients with hemophilia who have inhibitors against factor VIII or IX.

Teprasiran targets p53 and is being investigated for the prevention of acute kidney injury following cardiac surgery. By transiently silencing p53, teprasiran aims to protect renal tubular epithelial cells from apoptosis during ischemic stress.

Several siRNA candidates target complement pathway genes for the treatment of complement-mediated diseases, including geographic atrophy (a form of age-related macular degeneration) and complement-mediated kidney diseases. For example, an siRNA targeting complement component C5 is in development for geographic atrophy, with the goal of reducing complement-mediated retinal cell death.

The siRNA Drug landscape continues to expand, with ongoing trials targeting genes involved in cardiovascular disease, metabolic disorders, fibrosis, and rare genetic conditions.

Clinical Applications and Therapeutic Areas

Hereditary Diseases

siRNA therapy is particularly well-suited for hereditary diseases caused by gain-of-function mutations or haploinsufficiency. In gain-of-function diseases, the mutant allele produces a toxic protein, and silencing both the mutant and wild-type alleles can be beneficial if the wild-type protein is dispensable or if partial reduction is sufficient to prevent pathology. Hereditary transthyretin amyloidosis is the paradigmatic example: silencing TTR reduces both mutant and wild-type protein, and the resulting reduction in amyloid deposition slows disease progression.

For haploinsufficiency diseases, where a single functional allele is insufficient to produce normal protein levels, siRNA therapy must be designed to selectively silence the mutant allele while preserving expression of the wild-type allele. This can be achieved by targeting single-nucleotide polymorphisms (SNPs) that distinguish the mutant from the wild-type allele. This allele-specific silencing approach is being explored for diseases such as Huntington's disease, where silencing the mutant huntingtin allele while preserving the wild-type allele is expected to be therapeutically beneficial.

Oncology

siRNA therapy for cancer faces additional challenges compared to liver-targeted indications, primarily due to the difficulty of delivering siRNA to solid tumors. Nevertheless, several strategies are being pursued. One approach is to target oncogenes directly, such as silencing KRAS or MYC in tumors that depend on these genes for survival. Another approach is to silence genes involved in drug resistance, thereby sensitizing tumors to conventional chemotherapy.

Immuno-oncology applications of siRNA are also being explored. For example, siRNA targeting PD-L1 or other immune checkpoint molecules could be delivered to tumor cells to enhance anti-tumor immune responses. Additionally, siRNA can be used to silence immunosuppressive factors in the tumor microenvironment, such as TGF-β or IL-10, to promote T cell activation and tumor clearance.

The siRNA Technology platform is being adapted for cancer applications through the development of tumor-targeting delivery vehicles, including antibody-siRNA conjugates and peptide-siRNA complexes that recognize tumor-specific cell surface markers.

Infectious Diseases

siRNA therapy offers a potential approach for the treatment of viral infections, including hepatitis B virus (HBV), hepatitis C virus (HCV), and respiratory viruses. By targeting conserved regions of viral genomes, siRNA can silence viral gene expression and inhibit viral replication. For HBV, siRNAs targeting the viral X protein or the surface antigen have shown promise in preclinical studies and early clinical trials, reducing viral antigen levels and potentially enabling functional cure.

For respiratory viruses, such as respiratory syncytial virus (RSV) and influenza, siRNA can be delivered directly to the lungs via inhalation. This local delivery approach minimizes systemic exposure and allows for high local concentrations of siRNA at the site of infection. An inhaled siRNA targeting the RSV nucleocapsid gene was evaluated in clinical trials and demonstrated antiviral activity in infected volunteers, although it did not proceed to regulatory approval.

The COVID-19 pandemic has also spurred interest in siRNA therapeutics targeting SARS-CoV-2. siRNAs targeting conserved regions of the viral genome, such as the RNA-dependent RNA polymerase or the helicase genes, have shown antiviral activity in cell culture and animal models, though clinical development has not advanced significantly.

Methods to Study siRNA Therapy

In Vitro Assays

The study of siRNA therapy in the laboratory typically begins with cell culture experiments. Cells are transfected with siRNA using lipid-based transfection reagents, electroporation, or other methods—a process detailed in the siRNA Transfection resource. The efficiency of gene silencing is then measured at the mRNA level using quantitative reverse transcription PCR (RT-qPCR) and at the protein level using Western blotting or immunofluorescence.

For RT-qPCR, total RNA is extracted from cells 24–72 hours after transfection, reverse transcribed to cDNA, and amplified with gene-specific primers. The expression level of the target gene is normalized to a housekeeping gene, such as GAPDH or ACTB, and compared to cells transfected with a non-targeting control siRNA. A typical experiment might show 70–95% knockdown of the target mRNA, depending on the potency of the siRNA and the transfection efficiency.

Protein-level analysis by Western blotting provides confirmation that mRNA knockdown translates to reduced protein expression. The timing of protein knockdown lags behind mRNA knockdown by 12–24 hours, reflecting the half-life of the existing protein. For proteins with long half-lives, such as collagen or transthyretin, extended culture periods may be required to observe significant protein reduction.

Functional assays are used to assess the biological consequences of gene silencing. For example, if the target gene is involved in cell proliferation, cell viability or proliferation assays (such as MTT or BrdU incorporation) can be performed. If the target gene is involved in apoptosis, assays for caspase activation or annexin V staining can be used. These functional readouts are essential for determining whether the observed knockdown has phenotypic relevance.

In Vivo Models

Animal models are essential for evaluating the efficacy, safety, and pharmacokinetics of siRNA therapeutics. Mice are the most commonly used species, and both wild-type and genetically engineered mouse models are employed. For liver-targeted siRNAs, a single intravenous or subcutaneous injection is typically administered, and target gene silencing is measured in liver tissue 3–14 days later.

For disease models, the choice of model depends on the disease being studied. For hereditary transthyretin amyloidosis, transgenic mice expressing human mutant TTR are used. For hypercholesterolemia, mice fed a high-fat diet or deficient in the LDL receptor are used. For cancer studies, xenograft models—where human tumor cells are implanted into immunodeficient mice—are commonly employed, and siRNA is delivered either systemically or intratumorally.

Pharmacokinetic studies measure the concentration of siRNA in plasma and tissues over time, typically using hybridization-based assays or liquid chromatography-tandem mass spectrometry (LC-MS/MS). Biodistribution studies use fluorescently labeled or radiolabeled siRNA to track its accumulation in different organs. For GalNAc-siRNA conjugates, the liver is the primary site of accumulation, with peak concentrations reached within 1–4 hours after subcutaneous injection.

Toxicology studies in rodents and non-human primates assess the safety of siRNA therapeutics, including potential off-target effects, immune stimulation, and organ toxicity. These studies are required before clinical trials can proceed.

Computational Tools

Computational tools play a critical role in siRNA design and target prediction. Several algorithms are available for selecting siRNA sequences with high predicted potency and specificity. These algorithms incorporate rules based on thermodynamic properties, sequence features, and empirical data from large-scale silencing screens.

For off-target prediction, sequence alignment tools are used to identify mRNAs that share complementarity with the siRNA seed region. The seed region (nucleotides 2–8 of the guide strand) is the primary determinant of off-target effects, and siRNAs with seed regions that match many unrelated mRNAs are likely to cause non-specific silencing. Computational tools can rank siRNAs based on their predicted off-target potential, allowing researchers to select siRNAs with minimal predicted off-target activity.

The siRNA Knockdown resource provides guidance on experimental design, including the use of appropriate controls, optimization of transfection conditions, and validation of knockdown specificity.

Challenges and Limitations

Off-Target Effects

Off-target effects are a major concern in siRNA therapy. These effects arise when the guide strand binds to mRNAs with partial complementarity, particularly through seed region pairing, leading to silencing of unintended genes. The magnitude of off-target effects can be substantial, with some siRNAs silencing hundreds of genes in addition to their intended target.

Several strategies are used to minimize off-target effects. Chemical modifications, such as 2′-O-methylation of the seed region, can reduce binding to partially complementary mRNAs without affecting silencing of the fully complementary target. Additionally, careful selection of the guide strand to avoid seed sequences that are common in the transcriptome can reduce off-target potential. The use of bioinformatics tools to predict off-target interactions is standard practice in siRNA design.

Immunogenicity

The innate immune system can recognize siRNA as a foreign nucleic acid, triggering an inflammatory response. This recognition is mediated by pattern recognition receptors, including Toll-like receptors (TLRs) 3, 7, and 8, as well as the cytosolic sensors RIG-I and MDA5. TLR7 and TLR8 are activated by single-stranded RNA and certain siRNA motifs, particularly those containing GU-rich sequences. TLR3 recognizes double-stranded RNA, and RIG-I is activated by 5′-triphosphate RNA.

Immune stimulation can lead to non-specific gene silencing, cytokine release, and toxicity. To minimize immunogenicity, therapeutic siRNAs are heavily modified with 2′-O-methyl and 2′-fluoro nucleotides, which are not recognized by TLRs. Additionally, the 5′-triphosphate group, which is a potent RIG-I agonist, is removed or modified in synthetic siRNAs. The delivery vehicle also influences immunogenicity: LNPs can activate the complement system and trigger infusion-related reactions, while GalNAc conjugates are generally less immunostimulatory.

Stability and Biodistribution

The stability of siRNA in biological fluids is limited by the presence of nucleases. Unmodified siRNA has a half-life of only a few minutes in serum, and even chemically modified siRNAs have limited stability. The phosphorothioate backbone modification and 2′-O-methyl sugar modifications confer significant nuclease resistance, extending the half-life to hours or days.

Biodistribution is another challenge. After intravenous administration, siRNA accumulates primarily in the liver and spleen, which have fenestrated vasculature that allows extravasation of nanoparticles. Delivery to other tissues, such as the brain, lungs, or tumors, requires specialized delivery strategies. For brain delivery, approaches such as intrathecal injection or conjugation to ligands that cross the blood-brain barrier are being explored. For tumor delivery, enhanced permeability and retention (EPR) effects can promote accumulation in some tumors, but this is highly variable and often insufficient for therapeutic efficacy.

Common Pitfalls and Misconceptions

siRNA vs shRNA vs miRNA

A common source of confusion is the distinction between siRNA, short hairpin RNA (shRNA), and microRNA (miRNA). While all three are involved in RNAi-mediated gene silencing, they differ in their structure, biogenesis, and mechanism of action.

siRNA is a synthetic double-stranded RNA that is delivered exogenously to cells. It enters the RNAi pathway at the RISC loading step, bypassing Dicer processing. shRNA is a single-stranded RNA molecule that forms a hairpin structure and is typically expressed from a DNA vector delivered by viral transduction. shRNA is transcribed in the nucleus, exported to the cytoplasm, and processed by Dicer to generate siRNA duplexes that then load into RISC. The Microrna siRNA comparison is particularly important: miRNA is an endogenous, genomically encoded RNA that is processed from primary transcripts (pri-miRNA) by Drosha in the nucleus and Dicer in the cytoplasm. Mature miRNAs are typically 21–23 nucleotides long and silence target mRNAs through partial complementarity, primarily in the 3′ untranslated region, leading to translational repression and mRNA destabilization rather than direct cleavage.

The key mechanistic difference is that siRNA typically has perfect complementarity to its target and induces Ago2-mediated cleavage, while miRNA typically has partial complementarity and induces translational repression. However, this distinction is not absolute: siRNAs can also act through miRNA-like mechanisms when they have partial complementarity to off-target mRNAs, and some miRNAs can direct mRNA cleavage when they have perfect complementarity to their targets.

Misunderstanding RISC Loading

Another common misconception is that both strands of the siRNA duplex are loaded into RISC and are equally functional. In reality, only the guide strand is retained in the active RISC; the passenger strand is degraded. The selection of which strand becomes the guide strand is determined by the thermodynamic stability of the duplex ends, as described earlier. If both strands are equally stable at their 5′ ends, both strands can be loaded, leading to silencing of both the intended target and the passenger strand's targets. This is why careful design of the siRNA duplex to favor guide strand loading is essential.

Students also often misunderstand the role of Ago2 in RISC. Ago2 is not merely a scaffold protein; it is the catalytic engine of RISC. The PIWI domain of Ago2 adopts an RNase H-like fold and contains a conserved catalytic tetrad (DDEH) that coordinates divalent metal ions for phosphodiester bond cleavage. Without Ago2's slicer activity, siRNA-mediated mRNA cleavage would not occur.

Misconceptions About Delivery

A frequent misconception is that naked siRNA can be simply injected into the bloodstream and will find its way to target cells. In reality, naked siRNA is rapidly degraded, poorly taken up by cells, and cleared by the kidneys within minutes. Effective siRNA therapy requires a delivery system that protects the siRNA, targets it to the desired cells, and facilitates cytoplasmic delivery. The complexity of delivery is often underestimated by students new to the field.

Another misconception is that all cells take up siRNA-LNPs equally. In fact, LNP uptake is highly dependent on the cell type, with hepatocytes being particularly efficient due to their fenestrated endothelium and high endocytic activity. Other cell types, such as immune cells or neurons, are much more difficult to transfect with LNPs.

Summary and Future Directions

Key Takeaways

• siRNA therapy harnesses the endogenous RNAi pathway to silence disease-causing genes at the mRNA level, offering a versatile platform for treating a wide range of conditions.
• The mechanism involves Dicer processing (for endogenously expressed shRNA), RISC loading with Ago2, guide strand selection, and sequence-specific mRNA cleavage.
• Chemical modifications and delivery systems, particularly GalNAc conjugates and lipid nanoparticles, have enabled clinical translation of siRNA therapeutics.
• Several siRNA drugs have been approved for rare genetic diseases and hypercholesterolemia, with many more in clinical development.
• Major challenges include off-target effects, immunogenicity, and delivery to non-liver tissues, which are being addressed through improved design and novel delivery platforms.

Future Outlook

The field of siRNA therapy is advancing rapidly, with several emerging trends likely to shape its future. First, the development of novel delivery systems is expanding the range of targetable tissues beyond the liver. These include peptide-siRNA conjugates for muscle and adipose tissue, antibody-siRNA conjugates for immune cells, and polymer-based nanoparticles for tumor delivery. The Gene Therapy for Sickle Cell Disease resource illustrates how gene silencing approaches can complement gene editing strategies for hematologic disorders.

Second, combination therapies are being explored, where siRNA is used in conjunction with conventional drugs, monoclonal antibodies, or other nucleic acid therapeutics. For example, combining siRNA targeting PCSK9 with statin therapy provides additive LDL cholesterol reduction, and combining siRNA with immune checkpoint inhibitors may enhance anti-tumor immunity.

Third, the development of allele-specific siRNAs for the treatment of dominant genetic disorders is progressing, with clinical trials for Huntington's disease and other repeat expansion disorders underway. These approaches require careful design to selectively silence the mutant allele while preserving the wild-type allele.

Fourth, advances in chemical modification and delivery are enabling the development of siRNA therapeutics with improved durability of effect. GalNAc-siRNA conjugates already provide durable silencing lasting several months after a single dose, and further optimization may extend this to annual dosing.

Finally, the integration of artificial intelligence and machine learning into siRNA design is improving the prediction of potency, specificity, and off-target effects, accelerating the development of new siRNA therapeutics.

The success of siRNA therapy represents a triumph of basic RNA biology translated into clinical medicine. As delivery challenges are overcome and new applications are identified, siRNA therapy is poised to become an increasingly important modality in the treatment of human disease.

Frequently Asked Questions

What is siRNA therapy?

siRNA therapy is a therapeutic approach that uses small interfering RNA molecules to silence specific genes at the mRNA level. The siRNA is designed to be complementary to a target mRNA, and its delivery into cells triggers the RNA interference pathway, leading to degradation of the target mRNA and reduced production of the corresponding protein. This approach is used to treat diseases caused by overexpression of harmful genes or by the production of mutant proteins.

How does siRNA therapy work?

siRNA therapy works by exploiting the endogenous RNAi pathway. After delivery into the cytoplasm, the siRNA duplex is loaded into the RNA-induced silencing complex (RISC), where the guide strand is retained and the passenger strand is discarded. The guide strand directs RISC to complementary mRNA molecules, and the Ago2 protein within RISC cleaves the mRNA, leading to its degradation. This prevents translation of the mRNA into protein, effectively silencing the target gene.

What are some examples of siRNA therapies?

Approved siRNA therapies include patisiran and vutrisiran for hereditary transthyretin amyloidosis, givosiran for acute hepatic porphyria, lumasiran for primary hyperoxaluria type 1, inclisiran for hypercholesterolemia, and nedosiran for primary hyperoxaluria. Many additional siRNA therapeutics are in clinical trials for conditions such as hemophilia, complement-mediated diseases, and various cancers.

What diseases can siRNA therapy treat?

siRNA therapy can potentially treat any disease caused by the expression of a specific gene. Current applications include hereditary amyloidosis, porphyrias, hypercholesterolemia, hyperoxaluria, and hemophilia. Investigational applications include cancer, viral infections, neurodegenerative diseases, and fibrotic disorders. The main limitation is the ability to deliver siRNA to the affected tissues.

What are the main challenges of siRNA therapy?

The main challenges include delivery to target cells, off-target effects, immunogenicity, and stability. Naked siRNA is rapidly degraded and poorly taken up by cells, necessitating delivery vehicles or chemical conjugates. Off-target silencing can occur through seed region complementarity to unintended mRNAs. Immune stimulation can trigger inflammatory responses. Chemical modifications and careful design help address these challenges.

How is siRNA delivered to cells?

siRNA is delivered to cells using various approaches. Lipid nanoparticles encapsulate the siRNA and facilitate cellular uptake and endosomal escape. GalNAc conjugates target the asialoglycoprotein receptor on hepatocytes for liver-specific delivery. Other approaches include polymer-based nanoparticles, antibody-siRNA conjugates, peptide-siRNA complexes, and direct local delivery to tissues such as the eye or lung.

What is the difference between siRNA and shRNA?

siRNA is a synthetic double-stranded RNA molecule that is delivered exogenously to cells and enters the RNAi pathway at the RISC loading step. shRNA is a single-stranded RNA that forms a hairpin structure and is typically expressed from a DNA vector. shRNA is transcribed in the nucleus, exported to the cytoplasm, and processed by Dicer to generate siRNA duplexes. Both ultimately load into RISC and silence target genes, but they differ in their biogenesis and delivery requirements. The siRNA and miRNA distinction is also important: miRNA is an endogenous regulator that typically silences genes through partial complementarity, while siRNA is exogenous and typically silences through perfect complementarity and mRNA cleavage.

Key Takeaways

• siRNA therapy uses the RNAi pathway to silence disease-causing genes with high specificity and potency.
• The mechanism involves RISC loading, guide strand selection, and Ago2-mediated mRNA cleavage.
• Chemical modifications and delivery systems such as GalNAc conjugates and LNPs are essential for clinical efficacy.
• Multiple siRNA drugs have been approved, validating the platform for liver-targeted indications.
• Major challenges include delivery to non-liver tissues, off-target effects, and immunogenicity.
• Emerging trends include novel delivery vehicles, allele-specific silencing, and combination therapies.
• Understanding the distinctions between siRNA, shRNA, and miRNA is critical for proper experimental design and interpretation.

Further Reading

• Hu B et al. Therapeutic siRNA: state of the art. Signal transduction and targeted therapy. 2020. PubMed 32561705
• Sajid MI et al. siRNA Therapeutics for the Therapy of COVID-19 and Other Coronaviruses. Molecular pharmaceutics. 2021. PubMed 33945284
• Kumar A et al. Exploring dose and downregulation dynamics in lipid nanoparticles based siRNA therapy: Systematic review and meta-analysis. International journal of biological macromolecules. 2024. PubMed 39053830
• Kang JY et al. Engineered small extracellular vesicle-mediated NOX4 siRNA delivery for targeted therapy of cardiac hypertrophy. Journal of extracellular vesicles. 2023. PubMed 37795828
• Cheng J et al. Identifying fibroblast-derived sFRP2 as a therapeutic target and engineering siRNA therapy for uterine scarring. Nature communications. 2025. PubMed 40715133
• Singh A, Trivedi P, Jain NK. Advances in siRNA delivery in cancer therapy. Artificial cells, nanomedicine, and biotechnology. 2018. PubMed 28423924

Related Clinical & Scientific Guides

• MAPK Pathway: Mechanism, Function, and Clinical Relevance
• Mammalian Cell Culture Bioreactors: A Practical Guide
• Nucleotide Formation: Biosynthesis and Assembly of DNA/RNA Building Blocks